New Market Study Published: Brazil Pharmaceuticals & Healthcare Report Q3 2010

New Market Study Published: Brazil Pharmaceuticals & Healthcare Report Q3 2010
New Healthcare market report from Business Monitor International: "Brazil Pharmaceuticals & Healthcare Report Q3 2010"

Since the last quarter, we have revised our forecast slightly downward for Brazil as a result of concerns over the persisting fiscal slippage and the increasing role of politics in the economy in the run-up to October's elections. However, perhaps the most significant risk for Brazil's impressive sovereign rating credentials is the economy's high reliance on Chinese demand. BMI's Asia team have been highlighting the possibility of China's asset bubble bursting in the near term, which would significantly affect Brazil's pharmaceutical market.
However, the sector's resilience in light of the worst economic performance realised since 1998 means that we maintain our pharmaceutical sales forecast of double digit growth whilst monitoring closely the Chinese economy. We are currently projecting a compound annual growth rate (CAGR) of 14.37% through to 2014 in US dollar terms reaching a value of US$34.64bn.
In BMI's new Q310 Business Environment Ratings (BERs), Brazil is ranked fourth after the US, Canada and Puerto Rico in the Americas region, which has been expanded with the addition of countries such as Nicaragua and Honduras to cover 17 markets. Globally, it has slipped down two places from 15th to 17th, equal with China. While we maintain healthy optimism for the patented drug sector, we have noted that the generic drugs sub-sector is the fastest growing in Brazil. The market grew by 24% in local currency terms during 2009, marking yet another year of rapid market share gains for the industry. The result was within 1.4% of BMI projections, which stood at 22.6%. A study by the Foundation for Consumer Defence and Protection (Fundacao Procon) show price variations as high as 1,415% between reference drugs and their generic equivalents, as well as wide differences within their respective groups. Such disparity should continue to drive greater use and competition in the sector.
In our view a similar market dynamic, if not slightly more accelerated, will prevail going forward. BMI forecasts that the generic market will reach a value of BRL13.73bn (US$8.22bn) at a CAGR of 25.31% in US dollar terms over the next 5 years. In two separate transactions in Q110, US-based Valeant Pharmaceuticals acquired two Brazilian pharmaceutical companies for BRL97mn (US$55mn) and approximately BRL51mn (US$28mn). The companies, which specialise in branded generics and over-the-counter (OTC) medicines, had recorded annual sales of approximately US$28mn and US$19mn respectively, in 2009. Similarly, both companies posted revenue growth at a CAGR of nearly 15% over the past five years.
The Brazilian government's commitment to supporting its domestic pharmaceutical industry was one of the major factors to be put in the spotlight over the previous quarter. BMI expects this mentality to continue as long as it is not to the detriment of lowering drug prices. The government is also tackling the growing problem of counterfeit drugs by introducing serialisation for all medicinal packs. BMI notes that if foreign companies manage to penetrate the Brazilian pharmaceutical market now, they will benefit from significant commercial advantages.
For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/71628_brazil_pharmaceuticals_ ...
Report Table of Contents:
Executive Summary
SWOT Analysis
- Brazil Pharmaceuticals And Healthcare Industry SWOT
- Brazil Political SWOT
- Brazil Economic SWOT
- Brazil Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas Pharmaceutical Business Environment Ratings, Q310
- Limits Of Potential Returns
- Risks to Realisation of Returns
Brazil - Market Summary
Regulatory Regime
- Intellectual Property Environment
- Counterfeits
- Regulator Interference
- Compulsory Licensing
- Pricing and Reimbursement Issues
- Tax Burden on Pharmaceuticals
- OTC Regulations
- Advertising
- Other Regulatory Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- PROFARMA Initiative
- Research and Development
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Brazil - Economic Activity, 2007-2014
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Pharmaceutical Trade Forecast
- Medical Device Market Forecast
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Top 20 Pharmaceutical Companies In Brazil By Revenues 2008
- Innovative Drugmakers
- Innovative Drugmakers - Quarterly Developments
- Generic Drugmakers
- Generic Drugmakers - Quarterly Developments
- OTC Sector
- Distribution Sector
- Retail Market
Company Monitor
- Indigenous Manufacturing Sector
- Ache / Biosintetica
- EMS Sigma
- Eurofarma
- Medley
- Cristalia
- Foreign Companies
- Sanofi-Aventis
- Pfizer
- Merck & Co
- Novartis
- GlaxoSmithKline (GSK)
- Roche
- Nycomed (Altana Pharma)
- Merck KGaA
- Novo Nordisk
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables
About Business Monitor International
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.